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Abstract 
Two unknown impurities were detected in verapamil hydrochloride bulk drug 
using isocratic reversed-phase high performance liquid chromatography 
(HPLC). These impurities were isolated by preparative HPLC. Spectral data for 
the isolated impurities were collected. Based on the spectral data derived from 
two-dimensional nuclear magnetic resonance (2D-NMR) spectroscopy and 
mass spectrometry (MS), impurity-1 and impurity-2 were characterized as 
2-(3,4-dimethoxyphenyl)-3-methylbut-2-enenitrile and 2-(3,4-dimethoxyphenyl)-
2-isopropyl-3-methylbutanenitrile, respectively. 
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Introduction 
Verapamil hydrochloride,  chemically known as  2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-di-
methoxyphenyl)ethyl](methyl)amino}-2-(1-methylethyl)pentanenitrile  [1],  is an oral and 
intravenous calcium-channel blocking (CCB) agent. It is administered in the treatment of 
angina, hypertension, and supraventricular tachyarrhythmia. Verapamil hydrochloride is 
considered as a class IV antiarrhythmic agent and it is more effective than digoxin for 
controlling ventricular rate in patients with atrial fibrillation. 556  V. Srinivasan et al.:   
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Its principal physiological action is to inhibit the transmembrane influx of calcium ions into 
the heart and vascular smooth muscle cells. It improves the relationship between oxygen 
supply and consumption in the myocardium because oxygen demand is lowered directly 
as a result of the effect on the energy consuming metabolic process of the myocardial cells 
and indirectly due to a reduction of the afterload. Verapamil hydrochloride inhibits the influx 
of extracellular calcium across the myocardial and vascular smooth muscle cell 
membranes. It exerts its activity at the membrane surface of arterial smooth muscle cells 
and within conductile and contractile tissue in the myocardium. Calcium channels in 
myocardial and vascular smooth muscle cell membranes are selective and allow a slow 
inward flow of calcium, which contributes to excitation–contraction coupling and electrical 
discharge of conduction cells (plateau phase of the action potential) in the heart and 
vasculature. Verapamil hydrochloride inhibits this influx, possibly by deforming the 
channel, or by inhibiting ion-control gating mechanisms. Verapamil hydrochloride may also 
interfere with the release of calcium from the sarcoplasmic reticulum inside the cell. The 
decrease in intracellular calcium inhibits the contractile processes of the myocardial 
smooth muscle cells, resulting in dilation of the coronary and systemic arteries. These 
actions increase oxygen delivery to myocardial tissue and decrease total peripheral 
resistance, systemic blood pressure and afterload. This reduction in myocardial oxygen 
demand, cardiac workload and vascular tone is believed to be responsible for the drug’s 
beneficial effects in angina and its antihypertensive activities. Inhibition of calcium-
mediated smooth muscle contraction is also thought to be the explanation for verapamil 
hydrochloride’s action in the prevention and treatment of migraine [2–4]. 
Verapamil hydrochloride has also been described as an inhibitor of P-glycoprotein and is 
able to improve the response to chemotherapy by reducing the resistance of cancer cells 
against antineoplastic agents [5]. 
Recent studies on verapamil hydrochloride have revealed that a high dose of the drug is 
positive in the treatment of cluster headache. The dose of verapamil hydrochloride used 
for cluster headache is approximately double the dose used in cardiovascular disease, 
most likely because verapamil hydrochloride is a substrate for the efflux transporter P-
glycoprotein in the blood–brain barrier. Access of verapamil hydrochloride to the central 
nervous system is therefore limited. The effect of verapamil hydrochloride in cluster 
headache most likely takes place in the hypothalamus [6]. 
Verapamil  hydrochloride was synthesized in our laboratory, and when a sample  was 
subjected to high performance liquid chromatography (HPLC)  analysis,  we noted the 
presence of two unknown impurities which were isolated by preparative HPLC [7, 8]. The 
structural elucidation of these impurities is the objective of this work. 
The different analytical techniques reported so far for the determination of this drug along 
with associated impurities are capillary electrophoresis [9, 10], spectrophotometry [11, 12], 
HPLC [13, 14], atomic emission spectrometry [15], and the Rayleigh scattering method 
[16]. 
During quality control (QC) release analysis of the verapamil hydrochloride sample, two 
unknown impurities were observed at 0.68 RRT (relative retention time) and 1.07 RRT at 
the 0.10% level when the sample was analyzed using  chromatographic conditions 
published in the British Pharmacopoeia (BP) monograph for verapamil hydrochloride [17].   Detection, Isolation and Characterization of Impurities in Verapamil Hydrochloride   557 
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As per the  regulatory guidelines, pharmaceutical studies using a  sample of isolated 
impurities can be considered for safety assessment. Also, knowledge of the structure and 
source of the novel impurities is necessary to develop a more robust synthetic process. It 
is therefore essential to isolate and characterize unidentified impurities present in the drug 
sample.  A  sample was taken for the isolation of unknown impurities  using preparative 
HPLC and the isolated impurities  were  characterized using mass  spectrometry (MS), 
nuclear magnetic resonance (NMR) spectroscopy and infrared (IR) spectroscopy. To the 
best of our knowledge, this is the first report of these impurities detected at 0.68 RRT and 
1.07 RRT. 
 
(a) 
 
(b) 
 
(c) 
Fig. 1.   Typical chromatograms of (a) verapamil hydrochloride with impurities, (b) 
isolated impurity-1 and (c) isolated impurity-2. 
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Experimental 
Chemicals 
Acetonitrile, dipotassium hydrogen phosphate, formic acid and orthophosphoric acid, all 
HPLC grade, were purchased from Merck (Germany). 
Preparative high performance liquid chromatography (Prep HPLC) 
Shimadzu preparative HPLC equipment was  used with an  LC-8A pump, SCL-10A VP 
system controller, SPD-10AVP UV-VIS detector, FRC-10A fraction collector and 
Rheodyne injector with 5.0 mL loop (Shimadzu, Japan). The chromatographic separation 
was achieved on a Gemini C18 (Phenomenex, USA), 150 mm × 30.0 mm, 5 μm semi-
preparative column using a mobile phase containing a mixture of water and acetonitrile 
(65:35, v/v). The flow rate of the mobile phase was 20.0 mL/min and the wavelength was 
monitored at 278 nm. The injection volume was 1000 µL. The test concentration for the 
analysis was 50 mg/mL. The mobile phase was used as diluent for the preparation of test 
solutions. The data were recorded using Shimadzu’s LCsolution software. The eluent was 
monitored at 278 nm and the fractions collected were injected into the analytical HPLC 
apparatus to confirm the retention times. The fractions collected from preparative HPLC 
were evaporated using a Rotavapor. 
High performance liquid chromatography (analytical) 
The HPLC system was equipped with Quaternary gradient pumps, autosampler and 
autoinjector (Model LC2010CHT, Shimadzu,  Japan) connected to a  photodiode array 
detector controlled by LCsolution software (Shimadzu, Japan). A C18 column, ABZ+ 250 × 
4.6 mm, 5 μm (Sigma–Aldrich) was used with a mobile phase consisting of a mixture of 
6.97 g of dipotassium hydrogen phosphate in 1000 mL of water, pH adjusted to 7.2 with 
phosphoric acid. The eluent was monitored at 278 nm at a flow rate of 1.5 mL/min. The 
verapamil hydrochloride drug sample  was dissolved in mobile phase as diluent after 
sonicating the sample for about 5 min; the sample was further filtered through a 0.2 µm 
syringe filter and then injected into the HPLC apparatus. 
Mass spectrometry 
Direct ionization mass spectrometry was performed on a GCMS-2010 (Shimadzu, Japan) 
equipped with a DI source. The sample was introduced into the ion source with detector 
voltage 1.25 kV, detector temperature 300°C, ion source temperature 225°C and ionization 
energy 70 eV. The data were recorded using GC Solution software. 
High resolution mass spectrometry (HR-MS) 
The high resolution mass spectrometer consisted of an Agilent 1200 series high 
performance liquid chromatography system and a micrOTOFQ mass spectrometer (high 
sensitivity orthogonal time-of-flight instrument, Bruker Daltonics, Germany). All samples 
were analyzed on the micrOTOFQ mass spectrometer equipped with an electrospray 
ionization (ESI) source for accurate mass values. An in-house compound was used as an 
internal reference, and was introduced via a six-port divert valve using the Hystar and 
micrOTOF control software. The mass range was calibrated with ESI tuning mix solution 
(Part No. G2421A) from Agilent Technologies using quadratic fit. The sample was 
dissolved in methanol, sonicated for 10 min and diluted further to obtain a concentration of   Detection, Isolation and Characterization of Impurities in Verapamil Hydrochloride   559 
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10 µg/mL. Then,  using  an  autosampler,  5 µL of sample was introduced into  the flow 
injection of 0.1% formic acid solution in water and acetonitrile (1:1) at a flow rate of 200 
µL/min. The ESI tuning mix solution (1:10) in acetonitrile containing 10 µg/mL of in-house 
reference compound was infused via an infusion syringe to fill the 20 µL injection loop on a 
six-port divert valve. Using the micrOTOF control software, elution of the sample peak 
followed by that of the ESI tuning mix was programmed. 
NMR 
The 
1H, 
13C, and DEPT (Distortionless Enhancement by Polarization Transfer)  experi-
ments were performed with an JEOL AL 300 MHz FT-NMR spectrometer. All 2D-NMR 
experiments, Correlation Spectroscopy (COSY), Heteronuclear Single Quantum 
Correlation (HSQC) and Heteronuclear Multiple-Bond Coherence (HMBC) were performed 
using  a  gradient  probe  on  a  Bruker Avance 500 MHz FT-NMR spectrophotometer 
equipped with a 5 mm 
1H/
13C/X (
15N) three-channel triple resonance (TXI) probe; the pulse 
program used was employed from the pulse program library of Bruker. The data obtained 
were processed and analyzed using Topspin version 1.3 software (Bruker). CDCl3 was 
used as solvent. 
The 
1H and 
13C chemical shift values were reported on the δ scale in ppm, relative to 
tetramethylsilane (TMS) (δ 0.00 ppm) as internal standard. The coupling constants were 
expressed in Hertz. The IR spectra were recorded in the solid state as KBr dispersion 
using a Perkin-Elmer Spectrum One FT-IR spectrophotometer. 
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Fig. 2.   Chemical structures of verapamil hydrochloride and its impurities. 560  V. Srinivasan et al.:   
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Results and Discussion 
The isolated impurities were analyzed by HPLC and the HPLC purity was  99.2% for 
impurity-1 and 97.8% for impurity-2. The analytical HPLC chromatograms of verapamil 
hydrochloride along with impurities (including 16 impurities specified in BP) are shown in 
Fig. 1. Verapamil hydrochloride eluted at a retention time of 17.3 min, impurity-1 at 11.8 
min and impurity-2 at 18.5 min. The structures of verapamil hydrochloride and the isolated 
impurities are shown in Fig. 2. 
To obtain a preliminary structural insight, mass analysis was carried out on the isolated 
sample. The mass spectra of impurity-1 showed the molecular ions at m/z  217 and 
impurity-2 at m/z 261, respectively, whereas verapamil hydrochloride displayed molecular 
ions at m/z  454. The impurities were separated from verapamil hydrochloride by 
preparative HPLC so as to isolate larger amounts of impurity-1 and impurity-2 suitable for 
spectroscopic investigation. After isolation of impurity-1 and impurity-2, analytical HPLC 
chromatograms  are shown in Fig.  1. The NMR data of the isolated impurities were 
collected and the structures of the impurities have been assigned with the help of COSY, 
HSQC and HMBC data. 
Structural elucidation of impurity-1 
HR-MS data showed the mass of the molecular ion as a sodium adduct at m/z 240.0995 
[(corrected m/z 217.1097) (calculated 217.1103 for C13H15NO2)], which corresponds to the 
molecular formula C13H15NO2. 
The 
1H NMR data for  impurity-1 (Fig.  3b) were  compared with those of verapamil 
hydrochloride (Fig.  3a).  The 
1H NMR spectrum shows that  there are two methoxy 
functional groups, three aromatic protons and two methyl groups. The methyl signals are 
singlets which means that there is no proton on the neighboring carbon atom. 
The 
13C NMR data (Table 1) shows that there are three tertiary aromatic carbons and six 
quaternary carbons in the aromatic region which means that  the phenyl ring is tri-
substituted which accounts for three quaternary carbons and the presence of –CN 
accounts for another quaternary carbon. The peak at 118.98 ppm is due to the presence of 
–CN. The peak at 112.03  ppm could be due to the presence of a  quaternary carbon 
attached to the –CN group. 
From the DEPT 135 spectrum, it is clear that there are no –CH2 functional groups present 
in this moiety. From DEPT 135 and DEPT 90, it is also clear that there are three –CH 
groups in the aromatic region and two –CH3 groups present. No –CH group is present in 
the aliphatic region. 
The HMBC spectrum shows connectivity between –CH3 and two quaternary carbons at 
119 ppm and 110.5 ppm. 
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Fig. 3.  
1H NMR Spectra of a) verapamil b) impurity-1 and c) impurity-2 
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Tab. 1.  
1H and 
13C NMR assignments for impurity-1  
S.No  Shift (ppm)  Multiplicity  No.of H  Assignment 
1  0.89–0.91  Singlet  3  1 (2) 
2  1.03–1.05  Singlet  3  2 (1) 
3  3.90–3.91  Singlet  6  12,13 
4  6.84–6.91  Multiplet  3  7,8,11 
 
S.No  Shift (ppm)  Carbon  Assignment 
1  21.65  -CH3  C-1 
2  24.84  -CH3  C-2 
3  55.89  -CH3  C-12* 
4  55.93  -CH3  C-13* 
5  110.67  -CH  C-11 
6  110.97  -CH  C-8 
7  112.03  -C  C-4 
8  118.98  -C  C-5 
9  121.83  -CH  C-7 
10  126.66  -C  C-6 
11  148.84  -C  C-10* 
12  148.90  -C  C-9* 
13  153.88  -C  C-3 
* Tentative assignment 
 
The mass data for  verapamil hydrochloride (Fig.  4a) and impurity-1 (Fig.  4b) were 
compared. The data indicate that the molecular ion of verapamil hydrochloride is at m/z 
454[(M)
+] and the mass data for impurity-1 displayed a molecular ion at m/z 217[(M)
+]. 
Thus impurity-1 has 237 a.m.u. less than that of the molecular ion of verapamil 
hydrochloride and the mass of the impurity is nearer to the mass of one of the 
intermediates, (2RS)-2-(3,4-dimethoxyphenyl)-3-methylbutanenitrile.  
Further, the fragmentation pattern of impurity-1 at m/z 202 indicates the cleavage of one –
CH3 group, m/z 187 indicates the cleavage of a further –CH3 group, m/z 174 indicates the 
cleavage of an isopropyl group and m/z 148 indicates the cleavage of a –CN group. 
From the 
13C NMR data, it was inferred that there are two additional quaternary carbons, 
which may be due to an isopropene group. Based on the 2D-NMR and MS data, the 
structure of impurity-1 is characterized as 2-(3,4-dimethoxyphenyl)-3-methylbut-
2-enenitrile. 
   Detection, Isolation and Characterization of Impurities in Verapamil Hydrochloride   563 
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(a) 
 
(b) 
 
(c) 
Fig. 4.   Mass spectra of a) verapamil hydrochloride b) impurity-1 and c) impurity-2 
Structural elucidation of impurity-2 
HR-MS data showed the exact mass of the molecular ion as a sodium adduct at m/z 
284.1611  [(corrected  m/z  261.1713)  (calculated  261.1729 for C16H23NO2)], which 
corresponds to the molecular formula C16H23NO2. 
The 
1H NMR data of impurity-2 (Fig.  3c) were  compared with those of verapamil 
hydrochloride (Fig. 3a). This impurity has two methoxy (–OCH3) functional groups which 
are present in a similar region to verapamil hydrochloride. In the aromatic region, there are 
three protons and two sets of doublets around 1.0 ppm which could indicate a methyl 
group. There is another septet at 2.43 ppm which could be due to a –CH group. The 
presence of these two sets of peaks in the aliphatic region lead us to believe that there 
could be two isopropyl groups present in this impurity. 
 564  V. Srinivasan et al.:   
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Tab. 2.  
1H and 
13C NMR assignments for impurity-2 
S.No  Shift (ppm)  Multiplicity  No.of H  Assignment 
1  0.89–0.91  Doublet  6  1,1’ (2,2’) 
2  1.02–1.05  Doublet  6  2,2’ (1,1’) 
3  2.41–2.46  Septet  2  3,3’ 
4  3.89 & 3.90  Singlets  6  12,13 
5  6.81–6.89  Multiplet  3  7,8,11 
 
S.No  Shift (ppm)  Carbon  Assignment 
1  17.55  -CH3  C-1,1’ 
2  18.74  -CH3  C-2,2’ 
3  32.54  -CH  C-3,3’ 
4  55.72  -CH3  C-12* 
5  55.88  -CH3  C-13* 
6  57.37  -C-  C-4 
7  110.45  -CH  C-11 
8  111.60  -CH  C-8 
9  120.29  -CH  C-7 
10  121.97  -CN  C-5 
11  127.01  -C-  C-6 
12  148.24  -C-  C-9,10 
* Tentative assignment 
 
The 
13C NMR data (Table 1) show that there are five quaternary carbons including a –CN 
group; the peak at 121.97 ppm indicates the presence of a –CN functional group and there 
is one quaternary carbon present in the aliphatic unit. Considering the mass data, there 
are two –OCH3 functional groups, two sets of isopropyl groups, and –CN with a quaternary 
carbon. From the 
1H and 
13C NMR data, there are three –CH groups and three quaternary 
carbons present in the moiety.  
From the DEPT 135 spectrum,  it  is  clear that there is no –CH2  group present in this 
molecule. 
From the COSY NMR data, both –CH  groups are present in the same position which 
indicates that they are in the same chemical and magnetic environment.  
The  HMBC spectrum shows the connectivity of –CH (isopropyl) with the quaternary 
aromatic and aliphatic carbon  and also –CN. Both sets of –CH3  (isopropyl) show 
connectivity to the aliphatic quaternary carbon and –CN. Both the methoxy functional 
groups show direct connectivity to the phenyl ring. 
   Detection, Isolation and Characterization of Impurities in Verapamil Hydrochloride   565 
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(b) 
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Fig. 5.  
13C NMR Spectra of a) verapamil b) impurity-1 and c) impurity-2 566  V. Srinivasan et al.:   
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The mass data for  verapamil hydrochloride (Fig.  4a) and impurity-2 (Fig.  4c) were 
compared. The data indicate that the molecular ion peak of verapamil hydrochloride is at 
m/z 454[(M)
+] and the molecular ion peak of impurity-2 at m/z 261[(M)
+]. Thus, impurity-2 
has 193 a.m.u. less than that of the molecular ion of verapamil hydrochloride. Further 
fragmentation patterns of impurity-2 at m/z 235, 218 and 175 indicate the cleavage of a –
CN group, one isopropyl group followed by one more isopropyl group. The fragmentation 
due to m/z 138 indicates the presence of a dimethoxybenzene analog. This observation is 
also supported by proton NMR, where two sets of peaks were observed in the aliphatic 
region, and which indicates the presence of two isopropyl groups in this impurity. 
Based on the 2D-NMR and MS data, the structure of impurity-2 is  characterized as 
2-(3,4-dimethoxyphenyl)-2-isopropyl-3-methylbutanenitrile. 
Conclusion 
In the present study, two unknown impurities, impurity-1 and impurity-2, were detected by 
HPLC of verapamil hydrochloride bulk drug. The source for the formation of impurity-1 was 
due to contamination by acetone which was used as the cleaning solvent. The source for 
the formation of impurity-2 could be attributed to the addition of excess base (NaNH2) to 
the reaction mass. The attempt to isolate these impurities has been successful. They were 
isolated by preparative HPLC and characterized by spectroscopic studies. The structures 
of these impurities have not been reported previously in the literature. This study highlights 
the importance of impurity profiling of a drug substance. 
Based on the above spectral data, the molecular formula for impurity-1 was confirmed as 
C13H15NO2  and the corresponding structure was characterized as 2-(3,4-dimethoxy-
phenyl)-3-methylbut-2-enenitrile. Similarly, for impurity-2, the molecular formula was 
confirmed as C16H23NO2 and the corresponding structure was characterized as 2-(3,4-di-
methoxyphenyl)-2-isopropyl-3-methylbutanenitrile. 
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